Botto Lorenzo D, Lisi Alessandra, Robert-Gnansia Elisabeth, Erickson J David, Vollset Stein Emil, Mastroiacovo Pierpaolo, Botting Beverley, Cocchi Guido, de Vigan Catherine, de Walle Hermien, Feijoo Maria, Irgens Lorentz M, McDonnell Bob, Merlob Paul, Ritvanen Annukka, Scarano Gioacchino, Siffel Csaba, Metneki Julia, Stoll Claude, Smithells Richard, Goujard Janine
National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
BMJ. 2005 Mar 12;330(7491):571. doi: 10.1136/bmj.38336.664352.82. Epub 2005 Feb 18.
To evaluate the effectiveness of policies and recommendations on folic acid aimed at reducing the occurrence of neural tube defects.
Retrospective cohort study of births monitored by birth defect registries.
13 birth defects registries monitoring rates of neural tube defects from 1988 to 1998 in Norway, Finland, Northern Netherlands, England and Wales, Ireland, France (Paris, Strasbourg, and Central East), Hungary, Italy (Emilia Romagna and Campania), Portugal, and Israel. Cases of neural tube defects were ascertained among liveborn infants, stillbirths, and pregnancy terminations (where legal). Policies and recommendations were ascertained by interview and literature review.
Incidences and trends in rates of neural tube defects before and after 1992 (the year of the first recommendations) and before and after the year of local recommendations (when applicable).
The issuing of recommendations on folic acid was followed by no detectable improvement in the trends of incidence of neural tube defects.
Recommendations alone did not seem to influence trends in neural tube defects up to six years after the confirmation of the effectiveness of folic acid in clinical trials. New cases of neural tube defects preventable by folic acid continue to accumulate. A reasonable strategy would be to quickly integrate food fortification with fuller implementation of recommendations on supplements.
评估旨在降低神经管缺陷发生率的叶酸相关政策及建议的有效性。
通过出生缺陷登记处监测出生情况的回顾性队列研究。
13个出生缺陷登记处监测了1988年至1998年挪威、芬兰、荷兰北部、英格兰和威尔士、爱尔兰、法国(巴黎、斯特拉斯堡及中东地区)、匈牙利、意大利(艾米利亚 - 罗马涅和坎帕尼亚)、葡萄牙及以色列的神经管缺陷发生率。神经管缺陷病例在活产婴儿、死产及合法的妊娠终止情况中确定。政策及建议通过访谈和文献综述确定。
1992年(首次提出建议的年份)前后以及当地建议发布年份(如适用)前后神经管缺陷发生率及趋势。
叶酸相关建议发布后,神经管缺陷发生率趋势未见明显改善。
在叶酸在临床试验中证实有效性后的六年内,仅靠建议似乎并未影响神经管缺陷的趋势。可通过叶酸预防的神经管缺陷新病例仍在不断累积。一个合理的策略是迅速将食品强化与更全面地实施补充剂建议相结合。